Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
US10584352B2 · kind B2 · utility
15Cited by
1References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 8, 2018 |
| Grant date | Mar 10, 2020 |
| Priority date | — |
| Expiry date | Feb 8, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y301/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.